{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:15:45Z","timestamp":1792289745269,"version":"4.4.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.amjcard.2019.12.026","type":"journal-article","created":{"date-parts":[[2019,12,27]],"date-time":"2019-12-27T11:06:42Z","timestamp":1577444802000},"page":"907-915","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Meta-Analysis Evaluating Calcium Channel Blockers and the Risk of Peripheral Arterial Disease in Patients With Hypertension"],"prefix":"10.1016","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1137-4345","authenticated-orcid":false,"given":"Suchith","family":"Shetty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4865-8114","authenticated-orcid":false,"given":"Aaqib H.","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herman","family":"Feringa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramzi","family":"El Accaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4784-4513","authenticated-orcid":false,"given":"Saket","family":"Girotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2019.12.026_bib0001","first-page":"e38","article-title":"Heart disease and stroke statistics-2016 update: a report from the American Heart Association","volume":"133","author":"Mozaffarian","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2019.12.026_bib0002","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2019.12.026_bib0003","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","volume":"366","author":"Dahlof","year":"2005","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1016\/j.amjcard.2019.12.026_bib0004","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0022-2828(87)80008-1","article-title":"Model experiments on anticalcinotic and antiarteriosclerotic arterial protection with calcium antagonists","volume":"19","author":"Fleckenstein","year":"1987","journal-title":"J Mol Cell Cardiol"},{"issue":"Suppl 1","key":"10.1016\/j.amjcard.2019.12.026_bib0005","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1097\/00005344-199000161-00004","article-title":"Calcium channel blockers and atherosclerosis","volume":"16","author":"Henry","year":"1990","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.amjcard.2019.12.026_bib0006","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/0140-6736(90)91121-P","article-title":"Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the international nifedipine trial on antiatherosclerotic therapy (INTACT). INTACT group investigators","volume":"335","author":"Lichtlen","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2019.12.026_bib0007","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1097\/00004872-199715110-00019","article-title":"Clinical results of the verapamil in hypertension and atherosclerosis study. VHAS investigators","volume":"15","author":"Rosei","year":"1997","journal-title":"J Hypertens"},{"key":"10.1016\/j.amjcard.2019.12.026_bib0008","unstructured":"S Shetty, A Malik, REl Accaoui, S Girotra. Calcium channel blockers for prevention of peripheral vascular disease in hypertensive patients. 2019 PROSPERO. Available from: http:\/\/www.crd.york.ac.uk\/PROSPERO\/display_record.php?ID=CRD42019120523."},{"key":"10.1016\/j.amjcard.2019.12.026_bib0009","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.amjcard.2019.12.026_bib0010","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.amjcard.2019.12.026_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.amjcard.2019.12.026_bib0012","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jclinepi.2007.03.013","article-title":"Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis","volume":"61","author":"Wetterslev","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.amjcard.2019.12.026_bib0013","series-title":"Review Manager (RevMan) [Computer program]","year":"2014"},{"key":"10.1016\/j.amjcard.2019.12.026_bib0014","unstructured":"Thorlund K EJ, Wetterslev J, Brok J, Imberger G, Gluud C. User manual for trial sequential analysis (TSA) Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark, 2011: Available from:www.ctu.dk\/tsa."},{"key":"10.1016\/j.amjcard.2019.12.026_bib0015","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1006\/jmcc.1998.0867","article-title":"Membrane antioxidant effects of the charged dihydropyridine calcium antagonist amlodipine","volume":"31","author":"Mason","year":"1999","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.amjcard.2019.12.026_bib0016","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/ajh.2007.13","article-title":"Calcium channel blockers suppress cytokine-induced activation of human neutrophils","volume":"21","author":"Shima","year":"2008","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.amjcard.2019.12.026_bib0017","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1097\/00005344-199805000-00019","article-title":"Amlodipine inhibition of serum-, thrombin-, or fibroblast growth factor-induced vascular smooth-muscle cell proliferation","volume":"31","author":"Stepien","year":"1998","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.amjcard.2019.12.026_bib0018","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1161\/01.CIR.97.6.576","article-title":"Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent","volume":"97","author":"Zhang","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2019.12.026_bib0019","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0021-9150(89)90063-4","article-title":"Mechanism of antiatherogenic action of calcium antagonists","volume":"80","author":"Jackson","year":"1989","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjcard.2019.12.026_bib0020","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1161\/01.CIR.82.6.1940","article-title":"A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis","volume":"82","author":"Waters","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2019.12.026_bib0021","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1161\/01.ATV.16.3.425","article-title":"Evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. The REGRESS Study Group","volume":"16","author":"Jukema","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.amjcard.2019.12.026_bib0022","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1001\/jama.292.18.2217","article-title":"Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial","volume":"292","author":"Nissen","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2019.12.026_bib0023","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1097\/00004872-199816110-00014","article-title":"The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness","volume":"16","author":"Zanchetti","year":"1998","journal-title":"J Hypertens"},{"key":"10.1016\/j.amjcard.2019.12.026_bib0024","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1161\/01.CIR.102.13.1503","article-title":"Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators","volume":"102","author":"Pitt","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2019.12.026_bib0025","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1161\/01.CIR.0000039288.86470.DD","article-title":"Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial","volume":"106","author":"Zanchetti","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2019.12.026_bib0026","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.diabres.2008.10.014","article-title":"Comparison of effects of amlodipine and angiotensin receptor blockers on the intima-media thickness of carotid arterial wall (AAA study: amlodipine vs. ARB in atherosclerosis study)","volume":"83","author":"Ikeda","year":"2009","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.amjcard.2019.12.026_bib0027","doi-asserted-by":"crossref","first-page":"490","DOI":"10.5551\/jat.42101","article-title":"Effects of cilnidipine, an L\/N-Type calcium channel blocker, on carotid atherosclerosis in Japanese post-stroke hypertensive patients: results from the CA-ATTEND study","volume":"25","author":"Nezu","year":"2018","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.amjcard.2019.12.026_bib0028","doi-asserted-by":"crossref","first-page":"e57854","DOI":"10.1371\/journal.pone.0057854","article-title":"The effects of calcium channel blockers in the prevention of stroke in adults with hypertension: a meta-analysis of data from 273,543 participants in 31 randomized controlled trials","volume":"8","author":"Chen","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.amjcard.2019.12.026_bib0029","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1161\/HYPERTENSIONAHA.107.098475","article-title":"Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial","volume":"51","author":"Ogihara","year":"2008","journal-title":"Hypertension"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000291491931495X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000291491931495X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:32:52Z","timestamp":1757572372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000291491931495X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S000291491931495X"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2019.12.026","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Meta-Analysis Evaluating Calcium Channel Blockers and the Risk of Peripheral Arterial Disease in Patients With Hypertension","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2019.12.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}